Beijing Vas Medical Co. Ltd. raised ¥100 million (US$15M) in an angel financing round as well as obtaining marketing approval from China’s NMPA for its vascular interventional surgery robot. The company plans to use the funds to develop technology, update products, expand its team and make promotions.
Previse, formerly known as Capsulomics Inc., raised $3 million in seed financing to support the launch of its first laboratory-developed test (LDT), Esopredict. The precision medicine test is designed to detect Barrett’s esophagus (BE) and predict which BE patients will progress to esophageal cancer.
Startup Aiomic ApS received a capital injection in the form of a €1.3 million (US$1.4 million) convertible loan from Denmark’s Bioinnovation Institute (BII) that will allow the company to further develop and commercialize its artificial intelligence (AI)-driven Aiomic360 platform, which is designed to reduce the number of postoperative complications.
Yongrenxin Medical Instrument Co. Ltd. raised nearly $100 million in a series A funding round to build a health platform to treat heart failures. Sinovac Biotech Ltd. led the round.
Mvision AI Oy raised €5.4 million (US$5.8 million) in a post seed funding round to help accelerate the development of its artificial intelligence (AI)-powered automatic segmentation software, which automates and standardizes radiotherapy treatment for patients. Mvision aims to make same day cancer treatment a standard globally. The funding was led by J12 Ventures and Voima Ventures.
Mbiomics GmbH raised €13 million (US$14.2 million) in a first close of a series A round that will enable it to pivot from being a microbiome analytics firm to becoming a therapeutics developer.
RSS
